Sex Differences in Myocardial Steatosis Induced Left Ventricular

Status Recruiting

Clinical Trial Summary

To test the specific research questions, healthy men and age-matched healthy premenopausal females will be enrolled. Subjects will undergo cardiac magnetic resonance imaging and spectroscopy (MRI/MRS) to evaluate cardiac morphology/function and fat metabolism. To acutely elevate myocardial triglyceride content, subjects will be asked to abstain from eating for 2 days (reproducibly causes a significant and physiological increase in myocardial fat deposition, transiently). Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status. After screening, subjects will meet with the research coordinator or an investigator for a discussion, with opportunity for questions, before applicable consent forms are obtained. The subject will be screened for metal in or on their body and claustrophobia using a standard MR screening form. A venous blood sample will be taken for measurement of metabolic health, circulating hormones, and systemic inflammation. Imaging will include cine imaging for global morphology and function, tissue tagging for regional tissue deformation, spectroscopy for fat quantification. After baseline images of the heart are obtained, the subject will be asked to squeeze a MR-safe handgrip dynamometer at 30% of their maximum while images of the heart are obtained. Blood pressure will also be measured at rest and during stress. Each MRI will take approximately 90-120 minutes. Aim 1 will test the hypothesis that cardiac steatosis induced left ventricular dysfunction is sexually dimorphic, by comparing age-matched men and premenopausal women before and after 48 of fasting. Subjects will complete the MRI/MRS protocol described above before and after the fasting intervention. Aim 2 will test the hypothesis that estrogen is protective against cardiac steatosis-induced dysfunction, by suppressing ovarian sex hormones with a GnRH antagonist and repeating the fasting studies with and without estrogen add-back. 30 female subjects will be treated with GnRH antagonist and repeat the 48 hour fasting intervention and cardiac MRI/MRS protocol. 15 of the subjects will receive estrogen add-back using a transdermal patch, the other 15 subjects will receive a placebo patch. Aim 3 will test whether plasma and myocardial fatty acid composition is sexually dimorphic, by performing comprehensive plasma and myocardial lipidomics assessment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04671966
Study type	Interventional
Source	The University of Texas at Arlington
Contact	manall jaffery, MS
Phone	14694264030
Email	manalljaffery@gmail.com
Status	Recruiting
Phase	Phase 4
Start date	September 13, 2018
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04624412` - Different Intensities of Continuous Aerobic Exercises in Cardiac Rehab Phase 2	N/A
Completed	`NCT05563701` - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting	`NCT04561908` - Transcatheter Microguidewire Drilling for Transseptal Left Atrial Access	N/A
Active, not recruiting	`NCT06190743` - Perception of Cardiovascular Risk
Completed	`NCT04562636` - Evaluating a Messaging Campaign in the United States	N/A
Completed	`NCT04580095` - Artificial Intelligence for Improved Echocardiography	N/A
Recruiting	`NCT03277365` - MyGeneRank: A Digital Platform for Next-Generation Genetic Studies	N/A
Active, not recruiting	`NCT05553106` - Evaluation of Cognitive Status, Kinesiophobia, Physical Activity Level, and Functional Performance in Coronary Intensive Care
Completed	`NCT03429920` - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors	N/A
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Enrolling by invitation	`NCT03314818` - Natural History of Carotid Plaque as Determined by 3D Ultrasound	N/A
Withdrawn	`NCT03289104` - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX	N/A
Completed	`NCT02917213` - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed	`NCT02046902` - Developing and Testing a Personalized Evidence-based Shared Decision-making Tool for Stent Selection
Completed	`NCT01944254` - The Precision of Pulmonary Artery Cardiac Output-measurements in Spontaneously Breathing Patients	N/A
Completed	`NCT01909349` - Web-based Aftercare Intervention for Cardiac Patients	N/A
Recruiting	`NCT01457586` - Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery	Phase 4
Recruiting	`NCT01207167` - Mediators of Atherosclerosis in South Asians Living in America
Recruiting	`NCT01541163` - Heart and Ischemic STrOke Relationship studY	N/A
Completed	`NCT02645786` - Thyrotropin Over-suppression and Heart	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms